Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis

Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals, (Glenmark), has announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents aged 12 years and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA), earlier this year. The launch reflects Glenmark’s continued commitment to advancing its respiratory innovation journey and the Company’s continued progress in expanding access to differentiated therapies across global markets. Allergic rhinitis is a chronic condition in Brazil, affecting an estimated 20–30 per cent of the population, equivalent to nearly 40–60 million people. This disease burden highlights the need for effective, convenient, and differentiated treatment options for patients across the country. The launch of RYALTRIS introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine, olopatadine hydrochloride, and a corticosteroid, mometasone furoate, in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis. Commenting on the launch, Marco Cerato, Executive Vice President & Global Head – Innovative Business, Glenmark Pharmaceuticals said, “The launch of RYALTRIS in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach. As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals.” RYALTRIS is Glenmark’s first globally commercialized branded innovative product and has already been approved in 57 markets worldwide, including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China. The post Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis appeared first on Express Pharma.